Strategies to Overcome CAR T Roadblocks in the Real-World Practice Setting

Opinion
Video

Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers, and coordination of care to optimize real-world outcomes.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

Jason M. Broderick
April 17th 2025
Article

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its approval of the treatment last year.

Read More

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Binod Dhakal, MD, MS;Jordyn Sava
June 14th 2024
Podcast

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Listen

Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

Tony Berberabe, MPH
April 11th 2025
Article

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Read More

Advancing Myeloma Treatment With Blood-Based MRD Testing

Advancing Myeloma Treatment With Blood-Based MRD Testing

Jordyn Sava;Ben Derman, MD
February 15th 2024
Podcast

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

Jordyn Sava
April 10th 2025
Article

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

Read More

Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

Targeted Oncology Staff
April 8th 2025
Article

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

Read More